000 02463 a2200673 4500
005 20250518082208.0
264 0 _c20201007
008 202010s 0 0 eng d
022 _a1476-5551
024 7 _a10.1038/s41375-020-0714-3
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aQuijada-Álamo, Miguel
245 0 0 _aCRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
_h[electronic resource]
260 _bLeukemia
_c06 2020
300 _a1599-1612 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdenine
_xanalogs & derivatives
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xpharmacology
650 0 4 _aAtaxia Telangiectasia Mutated Proteins
_xgenetics
650 0 4 _aCRISPR-Cas Systems
650 0 4 _aCell Line, Tumor
650 0 4 _aChromosome Deletion
650 0 4 _aChromosomes, Human, Pair 11
_xgenetics
650 0 4 _aDrug Synergism
650 0 4 _aHumans
650 0 4 _aLeukemia, Lymphocytic, Chronic, B-Cell
_xgenetics
650 0 4 _aMice
650 0 4 _aMutagenesis, Site-Directed
_xmethods
650 0 4 _aMutation
650 0 4 _aPhthalazines
_xpharmacology
650 0 4 _aPiperazines
_xpharmacology
650 0 4 _aPiperidines
650 0 4 _aPoly (ADP-Ribose) Polymerase-1
_xantagonists & inhibitors
650 0 4 _aPoly(ADP-ribose) Polymerase Inhibitors
_xpharmacology
650 0 4 _aProto-Oncogene Proteins c-bcr
_xantagonists & inhibitors
650 0 4 _aPyrazoles
_xpharmacology
650 0 4 _aPyrimidines
_xpharmacology
650 0 4 _aXenograft Model Antitumor Assays
700 1 _aHernández-Sánchez, María
700 1 _aAlonso-Pérez, Verónica
700 1 _aRodríguez-Vicente, Ana E
700 1 _aGarcía-Tuñón, Ignacio
700 1 _aMartín-Izquierdo, Marta
700 1 _aHernández-Sánchez, Jesús María
700 1 _aHerrero, Ana B
700 1 _aBastida, José María
700 1 _aSan Segundo, Laura
700 1 _aGruber, Michaela
700 1 _aGarcía, Juan Luis
700 1 _aYin, Shanye
700 1 _aTen Hacken, Elisa
700 1 _aBenito, Rocío
700 1 _aOrdóñez, José Luis
700 1 _aWu, Catherine J
700 1 _aHernández-Rivas, Jesús María
773 0 _tLeukemia
_gvol. 34
_gno. 6
_gp. 1599-1612
856 4 0 _uhttps://doi.org/10.1038/s41375-020-0714-3
_zAvailable from publisher's website
999 _c30553905
_d30553905